iTeos Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
iTeos Therapeutics has a total shareholder equity of $663.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $751.8M and $88.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$571.26m |
| Equity | US$663.87m |
| Total liabilities | US$87.97m |
| Total assets | US$751.84m |
Recent financial health updates
Is iTeos Therapeutics (NASDAQ:ITOS) In A Good Position To Deliver On Growth Plans?
Aug 11
We Think iTeos Therapeutics (NASDAQ:ITOS) Can Afford To Drive Business Growth
Aug 24We Think iTeos Therapeutics (NASDAQ:ITOS) Can Easily Afford To Drive Business Growth
Feb 07Recent updates
Is iTeos Therapeutics (NASDAQ:ITOS) In A Good Position To Deliver On Growth Plans?
Aug 11iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism
Jul 09iTeos Therapeutics, Inc. (NASDAQ:ITOS) Looks Inexpensive But Perhaps Not Attractive Enough
Jan 25iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
Jan 10Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%
May 13Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding
Mar 21The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically
Aug 12iTeos Therapeutics GAAP EPS of $0.16 misses by $1.04
Aug 10iTeos Therapeutics: Too Many Unknowns
Jul 27News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts
May 11Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic
Nov 25We Think iTeos Therapeutics (NASDAQ:ITOS) Can Afford To Drive Business Growth
Aug 24iTeos Therapeutics: My Calculations Suggest Q3 Earnings Will Exceed $10 Per Share
Aug 15GlaxoSmithKline - iTeos deal intensifies competition in anti-TIGIT space: Piper Sandler
Jun 15We Think iTeos Therapeutics (NASDAQ:ITOS) Can Easily Afford To Drive Business Growth
Feb 07Is iTeos Therapeutics, Inc. (NASDAQ:ITOS) Popular Amongst Institutions?
Dec 16
iTeos Therapeutics EPS misses by $0.11
Nov 12Financial Position Analysis
Short Term Liabilities: ITOS's short term assets ($626.6M) exceed its short term liabilities ($34.7M).
Long Term Liabilities: ITOS's short term assets ($626.6M) exceed its long term liabilities ($53.3M).
Debt to Equity History and Analysis
Debt Level: ITOS is debt free.
Reducing Debt: ITOS has not had any debt for past 5 years.
Debt Coverage: ITOS has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ITOS has no debt, therefore coverage of interest payments is not a concern.